CN103073637B - Method for purifying ulinastatin by adsorption column chromatography - Google Patents

Method for purifying ulinastatin by adsorption column chromatography Download PDF

Info

Publication number
CN103073637B
CN103073637B CN201210597955.0A CN201210597955A CN103073637B CN 103073637 B CN103073637 B CN 103073637B CN 201210597955 A CN201210597955 A CN 201210597955A CN 103073637 B CN103073637 B CN 103073637B
Authority
CN
China
Prior art keywords
ulinastatin
elutriant
centrifugal
column chromatography
precipitation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210597955.0A
Other languages
Chinese (zh)
Other versions
CN103073637A (en
Inventor
林晓磊
孙建
刘翠珍
孙延年
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Jiulong biological medicine group Co., Ltd.
Original Assignee
QINGDAO JIULONG BIO-PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QINGDAO JIULONG BIO-PHARMACEUTICAL Co Ltd filed Critical QINGDAO JIULONG BIO-PHARMACEUTICAL Co Ltd
Priority to CN201210597955.0A priority Critical patent/CN103073637B/en
Publication of CN103073637A publication Critical patent/CN103073637A/en
Application granted granted Critical
Publication of CN103073637B publication Critical patent/CN103073637B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a method for purifying ulinastatin by adsorption column chromatography. In specific, fresh urine of a healthy adult man is taken as a raw material to prepare high-purity ulinastatin through modern high-end protein biochemical separation technology including chitin adsorption, ammonia water elution, ammonium sulfate salting-out, and adsorption column chromatography. The total yield coefficient can be increased to over 60%, and the total titer is greater than or equal to 4000 iu/mg.

Description

A kind of method of adsorpting column chromatography purifying ulinastatin
Technical field
The present invention relates to biological technical field, relate in particular to a kind of adsorpting column chromatography method of applying and prepare that yield is high, the method for the stable ulinastatin of tiring.
Background technology
Ulinastatin (Ulinastatin) is separation and purification a kind of acid glycoprotein out from NAM's freshly voided urine, it is a kind of proteinase inhibitor of wide spectrum, mainly synthetic in liver, discharged with urine by renal metabolism, and its low molecular weight compositions being decomposed to form also has the effect of very strong inhibition lytic enzyme.Ulinastatin is made up of 143 amino acid, relative molecular mass approximately 37000~43000, belong to proteinase inhibitor, the plurality of enzymes such as the serine protease such as trypsinase, Chymetin and granulocyte elastase, Unidasa, sulfydryl enzyme, plasmin are had to restraining effect, also there is stable lysosome membrane, suppress lysosomal enzyme release, suppress myocardial depressant factor (MDF) (MDF) and produce, remove the effect that oxyradical and inflammation-inhibiting medium discharge.Ulinastatin also can improve operation stimulates the abnormal and renal function of the lower immune function, Proteometabolism that cause to reduce, and prevents that operation from stimulating the damage to internal organs and cell causing and improving recurrent state while shock etc.
First Europe in 1909 report that human urine exists trypsin inhibitor, it is found that subsequently, when human body is infected, heating, tumour, gestation, shock, when performing the operation, give glucocorticosteroid etc. and stimulating, in human urine, UTI is active raises.Within 1985, first develop listing by Japan, be widely used in clinical as the medicine of acute pancreatitis, acute circulatory failure in Japan.
The inventor started the production technique research experiment to UTI from 2008, adopt the high-end biochemical isolation technique of modern protein to produce, the total recovery of UTI is brought up to more than 60%, total titer is not less than 4000iu/mg, stable processing technique, quality controllable.
Summary of the invention
The invention provides a kind of method of adsorpting column chromatography purifying ulinastatin, that the traditional method for extracting ulinastatin yields such as kaolin absorption, the absorption of acid resistance mixed mode are too low, the not high unsettled shortcoming of tiring in order to capture, adopt adsorpting column chromatography to carry out purifying ulinastatin, thereby improve ulinastatin yield, what ensured to tire is stable.
For solving the problems of the technologies described above, the present invention is achieved by the following technical solutions:
A method for adsorpting column chromatography purifying ulinastatin, is characterized in that: select resin absorption, special elutriant desorb to carry out purifying ulinastatin, total recovery can be brought up to more than 60%, total titer is not less than 4000iu/mg.
In invention technical scheme, also there is following technical characterictic: described adsorpting column chromatography comprises the steps:
1) ulinastatin roughing
Take the clarification urine that 1T pH is less than 6.5, constantly stir, after slowly adding the absorption completely of 16.5kg chitin, use ammoniacal liquor wash-out, pass through again 3.5kg ammonium sulfate precipitation, the precipitation, centrifugal being placed on of spending the night done vacuum-drying in the vacuum drier of water-retaining agent with Vanadium Pentoxide in FLAKES, obtains ulinastatin crude product after dry.
2) adsorpting column chromatography operation (taking 0.25L cylinder as example)
2.1) take ulinastatin crude product 1kg, with elutriant A dissolving, stir 30 minutes, centrifugal 20 minutes, leave and take centrifugate;
2.2) elutriant B balance for anion-exchange column, by the above-mentioned centrifugate good anion-exchange column of balance of flowing through, flow rate control is in 120~130mL/min left and right;
2.3) with elutriant B eluant solution, flow rate control, at 120~130mL/min, obtains elutriant;
2.4) by elutriant through ultra-filtration membrane, add phosphate buffered saline buffer ultrafiltration repeatedly, ultrafiltration, to 1/20th of its volume, obtains ultrafiltrated.
3) precipitation
In ultrafiltrated, add not low 95% ethanol precipitation 12 hours in the ratio of 1: 6, centrifugal, solid is again with dehydrated alcohol dehydration twice, and centrifugal, abandoning supernatant, leaves and takes throw out.
4) freeze-drying
Throw out is packed into and coiled into Freeze Drying Equipment, and freeze-drying obtains ulinastatin.
Through adjusting, gained ulinastatin total recovery, up to more than 60%, is measured by method shown in Chinese Pharmacopoeia, and total titer is up to more than 4000iu/mg.
Compared with prior art, advantage of the present invention and positively effect are:
Select adsorpting column chromatography purifying ulinastatin, can more effective removal multiple foreign protein wherein, and make its physico-chemical property and biological activity keep stable, thus make the indices of product all meet Chinese Pharmacopoeia standard.The more important thing is, by technique update and perfect, ulinastatin total recovery is reached more than 60%, total titer is not less than 4000iu/mg, brings huge economic benefit and social benefit.
Embodiment
Below in conjunction with specific embodiment, the invention will be further described, and restriction never in any form.
Embodiment 1
1) ulinastatin roughing
Take the clarification urine that 1T pH is less than 6.5, constantly stir, slowly add 16.5kg chitin, and measure with accurate pH test paper, regulate urine pH to 6.0; After absorption completely, with ammoniacal liquor wash-out 1h, then pass through 3.5kg ammonium sulfate precipitation, the precipitation of spending the night, centrifugal be placed on to put with Vanadium Pentoxide in FLAKES do vacuum-drying in the vacuum drier of water-retaining agent, after being dried, obtain ulinastatin crude product.
2) adsorpting column chromatography operation (taking 0.25L cylinder as example)
2.1) take ulinastatin crude product 1kg, with the elutriant A dissolving of 8.5L, stir 30 minutes, centrifugal 20 minutes, leave and take centrifugate;
2.2) the elutriant B balance of 2.5L for anion-exchange column, by the above-mentioned centrifugate good anion-exchange column of balance of flowing through, flow rate control is in 120mL/min left and right;
2.3) with the elutriant B eluant solution of 33L, flow rate control, at 120mL/min, obtains elutriant;
2.4) by elutriant through ultra-filtration membrane, add phosphate buffered saline buffer ultrafiltration repeatedly, ultrafiltration, to 1/20th of its volume, obtains the about 1.65L of ultrafiltrated.
3) precipitation
In ultrafiltrated, add not low 95% ethanol precipitation 12 hours in the ratio of 1: 6, centrifugal, solid is again with dehydrated alcohol dehydration twice, and centrifugal, abandoning supernatant, leaves and takes throw out.
4) freeze-drying
Throw out is packed into and coiled into Freeze Drying Equipment, and freeze-drying obtains ulinastatin.
Through adjusting, gained ulinastatin total recovery is 66%, measures by method shown in Chinese Pharmacopoeia, and total titer is up to 4312iu/mg.
Embodiment 2
1) ulinastatin roughing
Take the clarification urine that 1T pH is less than 6.5, constantly stir, slowly add 16.5kg chitin, and measure with accurate pH test paper, regulate urine pH to 6.0; After absorption completely, with ammoniacal liquor wash-out 1h, then pass through 3.5kg ammonium sulfate precipitation, the precipitation of spending the night, centrifugal being placed on Vanadium Pentoxide in FLAKES are done vacuum-drying in the vacuum drier of water-retaining agent, after being dried, obtain ulinastatin crude product.
2) adsorpting column chromatography operation (taking 0.25L cylinder as example)
2.1) take ulinastatin crude product 1kg, with the elutriant A dissolving of 8.5L, stir 30 minutes, centrifugal 20 minutes, leave and take centrifugate;
2.2) the elutriant B balance of 3.0L for anion-exchange column, by the above-mentioned centrifugate good anion-exchange column of balance of flowing through, flow rate control is in 130mL/min left and right;
2.3) with the elutriant B eluant solution of 33L, flow rate control, at 130mL/min, obtains elutriant;
2.4) by elutriant through ultra-filtration membrane, add phosphate buffered saline buffer ultrafiltration repeatedly, ultrafiltration, to 1/20th of its volume, obtains the about 1.65L of ultrafiltrated.
3) precipitation
In ultrafiltrated, add not low 95% ethanol precipitation 12 hours in the ratio of 1: 6, centrifugal, solid is again with dehydrated alcohol dehydration twice, and centrifugal, abandoning supernatant, leaves and takes throw out.
4) freeze-drying
Pack throw out into dish and put into into Freeze Drying Equipment, freeze-drying obtains ulinastatin.
Through adjusting, gained ulinastatin total recovery is 63%, measures by method shown in Chinese Pharmacopoeia, and total titer is up to 4123iu/mg.
The above, be only preferred embodiment of the present invention, is not the restriction of the present invention being made to other form, and any those skilled in the art may utilize the technology contents of above-mentioned announcement to be changed or be modified as the equivalent embodiment of equivalent variations.But every technical solution of the present invention content that do not depart from, any simple modification, equivalent variations and the remodeling above embodiment done according to technical spirit of the present invention, still belong to the protection domain of technical solution of the present invention.

Claims (1)

1. a method for purifying ulinastatin, the method is specially:
1) ulinastatin roughing
Take the clarification urine that 1T pH is less than 6.5, constantly stir, slowly add 16.5kg chitin, and measure with accurate pH test paper, regulate urine pH to 6.0; After absorption completely, with ammoniacal liquor wash-out 1h, then pass through 3.5kg ammonium sulfate precipitation, the precipitation of spending the night, centrifugal being placed on Vanadium Pentoxide in FLAKES are done vacuum-drying in the vacuum drier of water-retaining agent, after being dried, obtain ulinastatin crude product;
2) adsorpting column chromatography operation
2.1) take ulinastatin crude product 1kg, with the elutriant A dissolving of 8.5L, stir 30 minutes, centrifugal 20 minutes, leave and take centrifugate; The acetate buffer that described elutriant A is 0.01-0.3mol/L;
2.2) the elutriant B balance of 3.0L for anion-exchange column, by the above-mentioned centrifugate good anion-exchange column of balance of flowing through, flow rate control is the damping fluid of 0.01-0.5mol/L sodium-acetate and 0.1-5mol/LNaCl at elutriant B described in 130mL/mim;
2.3) with the elutriant B eluant solution of 33L, flow rate control, at 130mL/min, obtains elutriant;
2.4) by elutriant through ultra-filtration membrane, add phosphate buffered saline buffer ultrafiltration repeatedly, ultrafiltration, to 1/20th of its volume, obtains ultrafiltrated 1.65L; The concentration of described phosphate buffered saline buffer is 0.01-0.5mol/L;
3) precipitation
In ultrafiltrated, add 95% ethanol precipitation 12 hours in the ratio of 1: 6, centrifugal, solid is again with dehydrated alcohol dehydration twice, and centrifugal, abandoning supernatant, leaves and takes throw out;
4) freeze-drying
Pack throw out into dish and put into into Freeze Drying Equipment, freeze-drying obtains ulinastatin.
CN201210597955.0A 2012-12-30 2012-12-30 Method for purifying ulinastatin by adsorption column chromatography Active CN103073637B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210597955.0A CN103073637B (en) 2012-12-30 2012-12-30 Method for purifying ulinastatin by adsorption column chromatography

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210597955.0A CN103073637B (en) 2012-12-30 2012-12-30 Method for purifying ulinastatin by adsorption column chromatography

Publications (2)

Publication Number Publication Date
CN103073637A CN103073637A (en) 2013-05-01
CN103073637B true CN103073637B (en) 2014-06-25

Family

ID=48150353

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210597955.0A Active CN103073637B (en) 2012-12-30 2012-12-30 Method for purifying ulinastatin by adsorption column chromatography

Country Status (1)

Country Link
CN (1) CN103073637B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103819556A (en) * 2013-07-30 2014-05-28 青岛九龙生物医药有限公司 Method for improving yield of ulinastatin
CN104497133A (en) * 2014-12-23 2015-04-08 青岛康原药业有限公司 Method for purifying ulinastatin by using adsorption column chromatography and pharmaceutical composition containing ulinastatin
CN105384813A (en) * 2015-11-24 2016-03-09 青岛康原药业有限公司 Method for purifying ulinastatin by adsorption column chromatography and medicine composition for improving stability of ulinastatin
CN105384811A (en) * 2015-11-24 2016-03-09 青岛康原药业有限公司 Method for chromatographically purifying ulinastatin by adsorption column and drug composition improving solubility of ulinastatin
CN106333939A (en) * 2016-10-09 2017-01-18 常州亚环环保科技有限公司 Method for preparing medicinal transdermal material

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1824301A (en) * 2006-01-09 2006-08-30 广东天普生化医药股份有限公司 Purified ustading and its preparation method and medicinal composition containing said ustading
CN1931875A (en) * 2006-01-09 2007-03-21 广东天普生化医药股份有限公司 High purity ulinastatin and its prepn process and medicine composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1824301A (en) * 2006-01-09 2006-08-30 广东天普生化医药股份有限公司 Purified ustading and its preparation method and medicinal composition containing said ustading
CN1931875A (en) * 2006-01-09 2007-03-21 广东天普生化医药股份有限公司 High purity ulinastatin and its prepn process and medicine composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
乌司他丁效价测定方法的比较;邹金霞;《生命科学与医药卫生》;20110225(第2期);第63-64页 *
邹金霞.乌司他丁效价测定方法的比较.《生命科学与医药卫生》.2011,(第2期),第63-64页.

Also Published As

Publication number Publication date
CN103073637A (en) 2013-05-01

Similar Documents

Publication Publication Date Title
CN103073638B (en) Method for purifying ulinastatin via affinity chromatography
CN103073637B (en) Method for purifying ulinastatin by adsorption column chromatography
JP5948343B2 (en) Method for purifying human serum albumin from seeds of transgenic rice
CN104497133A (en) Method for purifying ulinastatin by using adsorption column chromatography and pharmaceutical composition containing ulinastatin
CN103724428A (en) Method for improving column efficiency purified ulinastatin through resin regeneration
CN105153297A (en) Method for separating and purifying alpha2-macroglobulin from Cohn component IV precipitate
CN104513308A (en) Method of resin regeneration for improving column efficiency and purifying ulinastatin, and drug composition containing ulinastatin
CN105384813A (en) Method for purifying ulinastatin by adsorption column chromatography and medicine composition for improving stability of ulinastatin
CN104497134A (en) Method for purifying ulinastatin by virtue of affinity chromatography and pharmaceutical compositions containing ulinastatin
CN104497135A (en) Method for purifying ulinastatin by virtue of virus inactivation/removal technology and pharmaceutical composition containing ulinastatin
Hultin et al. Specific unmasking of ribosomal proteins under the influence of chelating agents and increased ionic strength
CN102199192A (en) Method for separating functional polypeptide from tortoise-shell glue
CN104109204A (en) Method for separating and purifying recombinant human lactoferrins from paddy rice seeds
CN110183550A (en) A kind of preparation process of refined heparin sodium
CN105384811A (en) Method for chromatographically purifying ulinastatin by adsorption column and drug composition improving solubility of ulinastatin
CN105399819A (en) Method for purifying ulinastatin through affinity chromatography and pharmaceutical composition for improving stability of ulinastatin
CN105399818A (en) Method for purifying ulinastatin through affinity chromatography and pharmaceutical composition for improving re-dissolubility of ulinastatin
CN103146668A (en) Preparation technology of lumbrukinase dry powder
CN106924456A (en) One kind is for activating mitochondrial composition
CN101073666B (en) Method for producing kallidin proenzyme raw-material medicine
CN103880951B (en) A kind of method being prepared sterling ulinastatin by ulinastatin affinity chromatography medium
CN101525598B (en) Method for purifying human urinary trypsin inhibitor
CN108059670A (en) A kind of ulinastatin purification process based on affinity column
CN105399820A (en) Method for purifying ulinastatin by improving column efficiency through resin regeneration and pharmaceutical composition for improving stability of ulinastatin
CN104419695B (en) The preparation of the bionical affinitive material of chymotrypsinogen and chymotrypsin purification process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 266100 Zhuzhou Road, Laoshan District, Shandong, No. 97, No.

Patentee after: Qingdao Jiulong biological medicine group Co., Ltd.

Address before: 266100 Zhuzhou Road, Laoshan District, Shandong, No. 97, No.

Patentee before: Qingdao Jiulong Bio-Pharmaceutical Co., Ltd.

CP01 Change in the name or title of a patent holder